Longboard Pharmaceuticals ( (LBPH) ) has issued an announcement.
Lundbeck is set to acquire Longboard Pharmaceuticals in a strategic deal valued at approximately $2.6 billion, aiming to bolster its neuroscience pipeline. This acquisition will enhance Lundbeck’s presence in neuro-rare conditions, particularly with Longboard’s bexicaserin, a promising treatment for Developmental and Epileptic Encephalopathies (DEEs). The agreement offers Longboard shareholders $60 per share, a significant premium, and is expected to close by the fourth quarter of 2024, subject to regulatory approvals.
Learn more about LBPH stock on TipRanks’ Stock Analysis page.
